RT @victoriacyanide
From #JPM23: @GileadSciences to initiate TWO ph3 trials with #GS5245 (#obeldesivir):

OAKTREE: in standard risk patients, incl pts in the US

BIRCH: high risk pts VERSUS PLACEBO, which is already enrolling (NCT05603143)

#GS441524 prodrug! 💊

https://s29.q4cdn.com/585078350/files/doc_presentation/2023/01/GILD-JPM-Presentation-9-January-2023.pdf